4.8 Article

Contemporary Management of Cardiogenic Shock A Scientific Statement From the American Heart Association

Journal

CIRCULATION
Volume 136, Issue 16, Pages E232-E268

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIR.0000000000000525

Keywords

AHA Scientific Statements; delivery of health care; disease management; shock, cardiogenic

Funding

  1. St. Jude Medical
  2. Abbott Vascular
  3. AstraZeneca
  4. Abiomed
  5. St. Jude
  6. Cardiac Assist
  7. Maquet
  8. Daiichi Sankyo
  9. Gilead Sciences
  10. Janssen Pharmaceuticals
  11. AHA
  12. Novartis
  13. Merck
  14. European Union
  15. Medtronic Foundation
  16. Pfizer
  17. Bristol Myers Squibb

Ask authors/readers for more resources

Cardiogenic shock is a high-acuity, potentially complex, and hemodynamically diverse state of end-organ hypoperfusion that is frequently associated with multisystem organ failure. Despite improving survival in recent years, patient morbidity and mortality remain high, and there are few evidence-based therapeutic interventions known to clearly improve patient outcomes. This scientific statement on cardiogenic shock summarizes the epidemiology, pathophysiology, causes, and outcomes of cardiogenic shock; reviews contemporary best medical, surgical, mechanical circulatory support, and palliative care practices; advocates for the development of regionalized systems of care; and outlines future research priorities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available